ORIGINAL ARTICLE A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension Ronald J. Hogg & Angela Delucchi & Graciela Sakihara & Thomas G. Wells & Frank Tenney & Donald L. Batisky & Jeffrey L. Blumer & Beth A. Vogt & Man-Wai Lo & Elizabeth Hand & Deborah Panebianco & Ronda Rippley & Wayne Shaw & Shahnaz Shahinfar Received: 28 August 2006 / Accepted: 14 September 2006 / Published online: 10 January 2007 # IPNA 2007 Abstract The pharmacokinetic (PK) parameters of lisino- pril were obtained in 46 children aged 6 months to 15 years. A lisinopril suspension (0.15 mg/kg per day) was admin- istered to patients <6 years of age; the remaining children received lisinopril tablets, the daily dose being adjusted according to body weight, i.e., 2.5 mg if <25 kg, 5 mg if 25–45 kg, and 10 mg if >45 kg. Blood was drawn predose and on eight occasions postdose in children aged 4–15 years, and on five occasions in those aged <4 years. PK data are reported for the 46 children in terms of age groups: Group I (n =9), aged 6–23 months; Group II (n =8), aged 2–5 years; Group III (n =12), aged 6–11 years; Group IV (n =17), aged 12–15 years. The dose of lisinopril ranged from 3.07 mg/m 2 per day in Group I to 4.78 mg/m 2 per day in Group IV. C max of lisinopril, which occurred 5–6 h postdose, varied from 22 ng/ml in Groups I and II to 44 ng/ml in Groups III and IV; AUC 0–24 h ranged from 301–311 ng·h/ml in Groups I and II to 550–570 ng·h/ml in Groups III and IV. No serious adverse events related to lisinopril were reported. Keywords Children . Hypertension . Lisinopril . Multicenter . Pharmacokinetics Introduction Although angiotensin converting enzyme inhibitors (ACEi’ s) are widely used in the treatment of pediatric hypertension, there have been few studies to examine the response of children to these drugs. Recent publications Pediatr Nephrol (2007) 22:695–701 DOI 10.1007/s00467-006-0399-5 R. J. Hogg (*) St. Joseph’ s Hospital and Medical Center, 222 W. Thomas Rd., Suite 410, Phoenix, AZ 85013, USA e-mail: Ronald.Hogg@chw.edu A. Delucchi Luis Calvo Mackenna Hospital, Santiago, Chile G. Sakihara Instituto Especializado de Salud del Niño, Lima, Peru T. G. Wells Arkansas Children’ s Hospital, University of Arkansas for Medical Sciences, Little Rock, AR 72202, USA F. Tenney Louisiana State University Medical Center, Shreveport, LA 71130-3932, USA D. L. Batisky Pediatric Clinical Trials International, Columbus Children’ s Hospital, Columbus, OH 43205, USA J. L. Blumer : B. A. Vogt Case Western Reserve University, Rainbow Babies and Children’ s Hospital, Cleveland, OH 44106-6019, USA M.-W. Lo : E. Hand : D. Panebianco : R. Rippley : W. Shaw : S. Shahinfar Merck Research Laboratories, West Point, PA 19486, USA